Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

USC researchers have developed an innovative type of cancer-fighting immune cell, the EchoBack CAR T-cell, that uses focused ...

Hannah Abrams, MD, discusses the key takeaways of research into nonmedical barriers to HCT and CAR T therapy. Research led by Hannah Abrams, MD, fellow in hematolog-oncology at Fred Hutch Cancer ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Event details are available on the Immix website in the Presentation & Events section at https://immixbio.com/investors/#investor-presentation.

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Anixa Biosciences, Inc.’s ANIX share price has surged by 6.32%, which has investors questioning if this is right time to sell ...

The gross proceeds to CERo from the offering are expected to be up to $8 million, including $5 million expected to be received through the investment of securities at the first closing, and up to $3 ...

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...